Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Research | December 09, 2025 | December 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 09, 2025 · Filed December 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,833 |
Reported balance
After 2025-12-09 transaction · row 1
1 source rowRow 1 · 2025-12-09 · Tax withholding · Disposed 4,229 · Balance 47,833 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 4,375 |
Reported balance
Holding disclosure · report date 2025-12-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,375 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2024 Filed Mar 15, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 20,000 | $399.66 | $7,993,200.00 |
DisclosureSEC source: 0001968202-24-000086 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 7,657 | $856.71 | $6,559,828.47 |
DisclosureSEC source: 0001968202-23-000055 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,306 Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 669 | $844.09 | $564,696.21 |
DisclosureSEC source: 0001883850-23-000089 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,963 Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 5,105 | $844.09 | $4,309,079.45 |
DisclosureSEC source: 0001883850-23-000089 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,632 Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,473 | $0.00 Strike: $843.79 | $0.00 |
DisclosureSEC source: 0001883850-23-000089 · edgardoc.xml · derivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,473 Underlying: Common Stock · 11,473 shares Expires 2033-12-08 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 3,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000089 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,737 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2025 and 50% on December 8, 2027. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 883 | $843.79 | $745,066.57 |
DisclosureSEC source: 0001883850-23-000089 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,538 Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 184 | $821.46 | $151,148.64 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 14 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,421 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F10 · price: Represents volume-weighted average price of sales of 184 shares of Company stock on December 5, 2023 at prices ranging from $821.39 to $821.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 345 | $820.54 | $283,086.30 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 13 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,605 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F9 · price: Represents volume-weighted average price of sales of 345 shares of Company stock on December 5, 2023 at prices ranging from $820.27 to $820.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 973 | $819.57 | $797,441.61 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 12 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,950 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F8 · price: Represents volume-weighted average price of sales of 973 shares of Company stock on December 5, 2023 at prices ranging from $819.03 to $819.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,333 | $818.59 | $1,091,180.47 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 11 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,923 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F7 · price: Represents volume-weighted average price of sales of 1,333 shares of Company stock on December 5, 2023 at prices ranging from $818.07 to $818.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,881 | $817.36 | $1,537,454.16 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 10 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,256 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F6 · price: Represents volume-weighted average price of sales of 1,881 shares of Company stock on December 5, 2023 at prices ranging from $817.04 to $817.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 829 | $816.46 | $676,845.34 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 9 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,137 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F5 · price: Represents volume-weighted average price of sales of 829 shares of Company stock on December 5, 2023 at prices ranging from $816.01 to $816.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 155 | $815.97 | $126,475.35 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,966 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F4 · price: Represents volume-weighted average price of sales of 155 shares of Company stock on December 5, 2023 at prices ranging from $815.90 to $815.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 58 | $814.06 | $47,215.48 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,121 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 167 | $813.66 | $135,881.22 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,179 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F3 · price: Represents volume-weighted average price of sales of 167 shares of Company stock on December 5, 2023 at prices ranging from $813.00 to $813.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 372 | $812.57 | $302,276.04 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,346 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F2 · price: Represents volume-weighted average price of sales of 372 shares of Company stock on December 5, 2023 at prices ranging from $812.26 to $812.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 103 | $811.37 | $83,571.11 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,718 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 136 | $810.38 | $110,211.68 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,821 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $270.43 | $0.00 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · derivative · entry 16 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F11 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 13,464 | $813.58 | $10,954,041.12 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,957 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 20,000 | $270.43 | $5,408,600.00 |
DisclosureSEC source: 0001968202-23-000046 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 19 | $805.00 | $15,295.00 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · nonDerivative · entry 13 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,421 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 19 | $804.89 | $15,292.91 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · nonDerivative · entry 12 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,440 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 330 | $803.38 | $265,115.40 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · nonDerivative · entry 11 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,459 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F10 · price: Represents volume-weighted average price of sales of 330 shares of Company stock on November 14, 2023 at prices ranging from $803.18 to $803.69. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 347 | $802.63 | $278,512.61 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · nonDerivative · entry 10 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,789 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F9 · price: Represents volume-weighted average price of sales of 347 shares of Company stock on November 14, 2023 at prices ranging from $802.17 to $802.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 877 | $801.56 | $702,968.12 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · nonDerivative · entry 9 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,136 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F8 · price: Represents volume-weighted average price of sales of 877 shares of Company stock on November 14, 2023 at prices ranging from $801.01 to $801.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 382 | $800.55 | $305,810.10 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · nonDerivative · entry 8 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,013 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F7 · price: Represents volume-weighted average price of sales of 382 shares of Company stock on November 14, 2023 at prices ranging from $800.31 to $800.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,601 | $799.48 | $1,279,967.48 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · nonDerivative · entry 7 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,395 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F6 · price: Represents volume-weighted average price of sales of 1,601 shares of Company stock on November 14, 2023 at prices ranging from $799.00 to $799.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,614 | $798.63 | $1,288,988.82 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · nonDerivative · entry 6 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,996 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F5 · price: Represents volume-weighted average price of sales of 1,614 shares of Company stock on November 14, 2023 at prices ranging from $798.00 to $798.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 204 | $797.79 | $162,749.16 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · nonDerivative · entry 5 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,610 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F4 · price: Represents volume-weighted average price of sales of 204 shares of Company stock on November 14, 2023 at prices ranging from $797.09 to $797.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 347 | $795.38 | $275,996.86 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · nonDerivative · entry 4 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,814 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F3 · price: Represents volume-weighted average price of sales of 347 shares of Company stock on November 14, 2023 at prices ranging from $795.02 to $795.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 752 | $794.57 | $597,516.64 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · nonDerivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,161 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F2 · price: Represents volume-weighted average price of sales of 752 shares of Company stock on November 14, 2023 at prices ranging from $794.03 to $794.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $270.43 | $0.00 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · derivative · entry 15 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. F11 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 13,508 | $795.69 | $10,748,180.52 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · nonDerivative · entry 2 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,913 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 20,000 | $270.43 | $5,408,600.00 |
DisclosureSEC source: 0001968202-23-000042 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023. Read SEC document |
| May 09, 2023 Filed May 10, 2023 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-23-000013 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,421 Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,238 | $0.00 Strike: $726.53 | $0.00 |
DisclosureSEC source: 0001883850-22-000135 · edgardoc.xml · derivative · entry 3 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,238 Underlying: Common Stock · 15,238 shares Expires 2032-12-16 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 4,129 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000135 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,747 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 16, 2024 and 50% on December 16, 2026. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 492 | $753.28 | $370,613.76 |
DisclosureSEC source: 0001883850-22-000120 · edgardoc.xml · nonDerivative · entry 1 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,618 Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $749.92 | $7,499.20 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 23 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,110 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $744.01 | $74,401.00 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 22 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,120 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 21 | $742.25 | $15,587.25 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 21 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,220 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 66 | $741.61 | $48,946.26 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 20 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,241 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 66 shares of Company stock on November 15, 2022 at prices ranging from $741.61 to $741.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $736.40 | $1,472.80 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 19 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,307 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 64 | $734.59 | $47,013.76 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 18 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,309 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 21 | $733.42 | $15,401.82 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 17 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,373 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 21 shares of Company stock on November 15, 2022 at prices ranging from $733.41 to $733.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 78 | $732.40 | $57,127.20 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 16 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,394 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 532 | $731.49 | $389,152.68 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 15 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,472 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 532 shares of Company stock on November 15, 2022 at prices ranging from $731.03 to $731.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 315 | $730.57 | $230,129.55 |
DisclosureSEC source: 0001883850-22-000096 · edgardoc.xml · nonDerivative · entry 14 MURPHY ANDREW J · CIK 0001796226 · EVP Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,004 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 315 shares of Company stock on November 15, 2022 at prices ranging from $730.01 to $730.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.